Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 489-494 , May 2006

Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors

  • Hirofumi Hanaoka

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • Graduate School of Medicine, Gunma University, Showa-machi, Maebashi 371-8511, Japan
    • ,
  • Takahiro Mukai

      Affiliations

    • Graduate School of Medicine, Kyoto University, Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
    • Graduate School of Pharmaceutical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Hirokazu Tamamura

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan
    • ,
  • Tomohiko Mori

      Affiliations

    • Graduate School of Medicine, Kyoto University, Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • Seigo Ishino

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • ,
  • Kazuma Ogawa

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • ,
  • Yasuhiko Iida

      Affiliations

    • Graduate School of Medicine, Gunma University, Showa-machi, Maebashi 371-8511, Japan
    • ,
  • Ryuichiro Doi

      Affiliations

    • Graduate School of Medicine, Kyoto University, Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
    • ,
  • Nobutaka Fujii

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • ,
  • Hideo Saji

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 75 753 4556; fax: +81 75 753 4568.

Received 7 October 2005 ,Revised 12 January 2006 ,Accepted 12 January 2006.

References 

  1. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127
  2. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 2001;12:313–335
  3. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–877
  4. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56
  5. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley RS. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cances Res. 2002;62:1832–1837
  6. Schrader AJ, Lechner O, Templin M, Dittmar KEJ, Machtens S, Mengel M, et al. CXCR4/CXCL12 expression and signaling in kidney cancer. Br J Cancer. 2002;86:1250–1256
  7. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167:1676–1686
  8. Uchida D, Begum NM, Almofti A, Nakashiro K, Kawamata H, Tateishi Y, et al. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003;290:289–302
  9. Masuda M, Nakashima H, Ueda T, Naba H, Ikoma R, Otaka A, et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12Lys7]-polyphemusin II). Biochem Biophys Res Commun. 1992;189:845–850
  10. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 1997;186:1389–1393
  11. Tamamura H, Arakaki R, Funakoshi H, Imai M, Otaka A, Ibuka T, et al. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12,Lys7]-polyphemusin II). Bioorg Med Chem. 1998;6:231–238
  12. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, et al. A low-molecular- weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998;253:877–882
  13. Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, et al. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett. 2000;10:2633–2637
  14. Tamamura H, Sugioka M, Odagaki Y, Omagari A, Kan Y, Oishi S, et al. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg Med Chem Lett. 2001;11:359–362
  15. Tamamura H, Sugioka M, Odagaki Y, Omagari A, Kan Y, Oishi S, et al. Corrigendum to “conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity”. [Bioorg. Med. Chem. Lett. 11 (2001) 359] Bioorg Med Chem Lett. 2001;11:2409
  16. Tamamura H, Omagari A, Hiramatsu K, Gotoh K, Kanamoto T, Xu Y, et al. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett. 2001;11:1897–1902
  17. Tamamura H, Hiramatsu K, Kusano S, Terakubo S, Yamamoto N, Trent JO, et al. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org Biomol Chem. 2003;1:3656–3662
  18. Arano Y, Uezono T, Akizawa H, Ono M, Wakisaka K, Nakayama M, et al. Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative. J Med Chem. 1996;39:3451–3460
  19. Arano Y, Akizawa H, Uezono T, Akaji K, Ono M, Funakoshi S, et al. Conventional and high-yield synthesis of DTPA-conjugated peptide: application of a monoreactive DTPA to DTPA-d-Phe1-octreotide synthesis. Bioconjug Chem. 1997;8:442–446
  20. Hesselgesser J, Liang M, Hoxie J, Greenberg M, Brass LF, Orsini MJ, et al. Identification and characterization of CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol. 1998;160:877–883
  21. Tamamura H, Omagari A, Hiramatsu K, Oishi S, Habashita H, Kanamoto T, et al. Certification of the critical importance of l-3-(2-naphthyl)alanine at position 3 of specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study. Bioorg Med Chem. 2002;10:1417–1426
  22. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–3450
  23. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530–3535
  24. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004;3:29–37
  25. Nagasawa T, Nakajima T, Tachibana K, Iizasa H, Bleul CC, Yoshie O, et al. Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A. 1996;93:14726–14729
  26. Moepps B, Frodl R, Rodewald HR, Bsggiolini M, Gierschik P. Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1α activation of Gi2 are differentially expressed in vivo. Eur J Immunol. 1997;27:2102–2112
  27. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WAP, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388–1392
  28. Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761–768
  29. Akizawa H, Takimoto H, Saito M, Iwado A, Mifune M, Saito Y, et al. Effect of carboxylation of N-terminal phenylalanine of 111In-DTPA (diethylenetriaminepentaacetic acid)-octreotide on accumulation of radioactivity in kidney. Biol Pharm Bull. 2004;27:271–272
  30. Bagutti C, Stolz B, Albert R, Bruns C, Pless J, Eberle AN. [111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo. Int J Cancer. 1994;58:749–755
  31. de Visser M, Janssen PJJM, Srinvasan A, Reubi JC, Waser B, Erion JL, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–1139
  32. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–1750
  33. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744–2753
  34. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835–1841
  35. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561–2567
  36. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003;550:79–83
  37. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004;64:4302–4308
  38. Takenaga M, Tamamura H, Hiramatsu K, Nakamura N, Yamaguchi Y, Kitagawa A, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun. 2004;320:226–232
  39. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604–8612

PII: S0969-8051(06)00008-4

doi: 10.1016/j.nucmedbio.2006.01.006

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 489-494 , May 2006

Article Tools

* Image Usage & Resolution